Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

sus temsirolimus in relapsed or refractory  MCL patients, RAY (MCL3001). This trial is a randomized, multi-center, open-label trial of ibrutinib as a mono-therapy versus temsirolimus in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen. The primary endpoint of the study is progression free survival when compared to temsirolimus. This global study, conducted by Janssen outside the US, is open and Janssen plans to enroll 280 patients.
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with newly diagnosed MCL, SHINE (MCL3002). This trial is a randomized, multi-center, double-blinded, placebo-controlled trial of ibrutinib plus bendamustine and rituximab versus placebo plus bendamustine and rituximab in subjects with newly diagnosed MCL. The primary endpoint of the study is progression free survival when compared to bendamustine and rituximab. Janssen plans to enroll 520 patients in this study.
  • Phase II study of ibrutinib in patients with mantle cell lymphoma who progress after bortezomib therapy, SPARK (MCL2001). This is a single-arm, multi-center trial of ibrutinib as a monotherapy in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is overall response rate. This global study, conducted by Janssen, is open and Janssen plans to enroll 110 patients worldwide.
  • Phase II study of ibrutinib in patients with mantle cell lymphoma who progress after bortezomib therapy, SPARK (MCL2001). This is a single-arm, multi-center trial of ibrutinib as a monotherapy in relapsed or refractory MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is overall response rate. This global study, conducted by Janssen,
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... BURLINGTON, Mass. , Aug. 20, 2014  Decision Resources Group ... , Russia , India ... approximately $1.6 billion in 2013, roughly equal to the size of ... forward, however, the BRIC market will experience much faster growth as ... the aging population. Other key findings from Decision Resources ...
    (Date:8/20/2014)... SAN JOSE, Calif. , Aug. 20, 2014 ... UCSD highlights the transformative collaboration between the school,s ... (IoT).  As part of the Intel® Software Academic ... between computer sciences and the human body.  ... The study exhibits the work of ...
    (Date:8/19/2014)... One of the major limitations in ... vascular supply. Nutrient and gas transport throughout synthetic ... for successful regeneration and integration into the patient’s ... vascularization and promote angiogenesis in a variety of ... and architecture, and enhancing scaffolds with stem cells. ...
    (Date:8/19/2014)... August 19, 2014 Cellgen ... raise $200,000 to fund a corporate lab for ... , This development is a critical component in ... care to the implementation of personalized medicine – ... practicing medicine. , Indiegogo contributions will support Cellgen’s ...
    Breaking Biology Technology:BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
    ... SAN FRANCISCO, Calif., Nov. 1, 2010 diaDexus, Inc. ... company focused on the development and commercialization of patent-protected ... in cardiovascular disease, today announced that the company, formerly ... Bulletin Board under the ticker symbol (VXGN), has been ...
    ... With... -- BOZEN, Sud-Tirol, Italy, November 1, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
    ... 30 Tibotec Pharmaceuticals (Tibotec) announced today the company will ... the phase 2 response-guided PILLAR study in treatment-naive patients with ... Annual Meeting of the American Association for the Study of ... be presented as part of a late-breaker oral presentation on ...
    Cached Biology Technology:diaDexus Announces Name Change From VaxGen 2diaDexus Announces Name Change From VaxGen 3Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 2Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 3Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 4Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 5Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 6Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 7Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 8Health Robotics Continues Worldwide Consolidation by Entering the Norwegian Market With Beckman Automation 9Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 2Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 3Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD 4
    (Date:8/20/2014)... are visible in in this image of the Para ... these were most likely intentionally set in order to ... forest or stand of trees where the land is ... include conversion of forestland to farms, ranches, or urban ... green of the Amazon Rainforest in the middle of ...
    (Date:8/20/2014)... Area Lyme Foundation, which aims to make Lyme disease ... research published in an upcoming issue of the Elsevier ... The findings show that ticks that carry Lyme ... making the threat of Lyme disease year-round. The research ... Health (CDPH) Vector-borne Disease Section and University of California, ...
    (Date:8/20/2014)... Research UK scientists have discovered that acral melanomas the ... Marley,s death are genetically distinct from other more common ... external) published in the journal Pigment Cell & Melanoma ... of the hands, soles of the feet, nail-beds and other ... of melanoma, it,s not caused by UV damage from the ...
    Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Scientists learn more about rare skin cancer that killed Bob Marley 2
    ... Pharmaceuticals report this week that they have successfully used RNA ... mice, an advance that could lead to new treatments for ... 1998 discovery of RNA interference the naturally occurring phenomenon ... nucleus to the protein-building machinery of the cell is disrupted ...
    ... New Delhi, Singapore and Washington DC (Dec 28, 2010) ... identify with political parties , according to an article in ... official journal of the Western Political Science Association (published by ... studied concepts in modern political science. Scholars have long held ...
    ... spotlight that illuminates an otherwise dark scene, attention brings to ... A new study by researchers at the Salk Institute for ... that primarily had been known for its role in the ... the mind,s spotlight. Their findings, published in the Dec. ...
    Cached Biology News:New RNA interference technique can silence up to 5 genes 2Seeing without looking 2
    ... Trap Time of Flight Mass Analyzer for superior sensitivity, mass accuracy, ... - 25,000 m/z, * Precursor ion selection range: 150 - 4000 ... 5 ppm with internal reference, * Dynamic range: 4 orders of ... ...
    ... pYD1 Yeast Display Vector is specifically designed ... the surface of Saccharomyces cerevisiae. Displayed proteins ... interact with known or putative ligands. pYD1 ... consists of two domains, Aga1 and Aga2, ...
    ... Oncostatin M (OSM) is a pleiotropic ... and Kaposis sarcoma cells. OSM inhibits the ... lines, simulates fibroblast, smooth muscle and Kaposis ... cells and low density lipoprotein receptor expression ...
    Mouse polyclonal antibody to BTAF1 - BTAF1 RNA polymerase II, B-TFIID transcription factor-associated, 170kDa (Mot1 homolog, S. cerevisiae)...
    Biology Products: